Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The purpose of this study is to estimate overall survival of Sintilimab+ oxaliplatin + capecitabine and placebo+ oxaliplatin + capecitabine, as first‐line treatment of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Epistemonikos ID: 8a81a1bd023d1167cdf4a3f53699c5039cc0bb77
First added on: May 21, 2024